Showing 5211-5220 of 7863 results for "".
- Study Links MRGPRX3 Expression to Chronic Pruritus in PN and ADhttps://practicaldermatology.com/news/study-links-mrgprx3-expression-to-chronic-pruritus-in-pn-and-ad/2486413/In a prospective analysis of skin biopsies, investigators reported significantly elevated cutaneous MRGPRX3 expression in lesional prurigo nodularis (PN) and atopic dermatitis (AD), alongside a notable association between MRGPRX3-related gene mutations and Black pa
- What New Secukinumab Data Mean for HS Patients: A Q&A with Dr. April Armstronghttps://practicaldermatology.com/news/what-new-secukinumab-data-mean-for-hs-patients-a-qa-with-dr-april-armstrong/2486412/In the following Q&A, Dr. April Armstrong, professor and chief of dermatology at UCLA and a study coauthor, talks with Practical Dermatology about the importance of new secukinumab data for patients with hidradenitis suppurativa (HS). Speaking on UCB's recently announced top
- Study: Dermatologists Rarely Prescribe GLP-1 Agents in Psoriasis, HS Cohorthttps://practicaldermatology.com/news/study-dermatologists-rarely-prescribe-glp-1-agents-in-psoriasis-hs-cohort/2486411/A new retrospective review identified a significant gap in care between eligibility for glucagon-like peptide-1 receptor agonists (GLP-1RAs) and real-world utilization among patients with psoriasis and hidradenitis suppurativa (HS).
- Cannabis Use Linked to Lower BCC Risk, No Change in Melanoma or cSCC: Studyhttps://practicaldermatology.com/news/cannabis-use-linked-to-lower-bcc-risk-no-change-in-melanoma-or-cscc/2486395/Cannabis use was linked with decreased incidince of basal cell carcinoma (BCC), but not cutaneous squamous cell carcinoma (cSCC) or malignant melanoma (MM), according to results from a newly presented poster. Researchers for t
- Prospective Data Show Comparable Performance Between AI and Dermatologistshttps://practicaldermatology.com/news/prospective-data-show-comparable-performance-between-ai-and-dermatologists/2486375/A new systematic review and meta-analysis of prospective studies suggests artificial intelligence (AI) systems can achieve diagnostic performance comparable to dermatologists in melanoma detection using dermoscopy. Investigato
- Analysis: Long Waits for Pediatric Dermatology Appointments Across UShttps://practicaldermatology.com/news/study-finds-long-waits-for-pediatric-dermatology-appointments-across-us/2486313/Children seeking dermatologic care in the US face long waits regardless of where they are referred, according to a research letter published online in JAMA Dermatology. Using a mystery caller design, investigators as
- Dermatology Residents Show Gains After Targeted Topical Formulation Educationhttps://practicaldermatology.com/news/dermatology-residents-show-gains-after-targeted-topical-formulation-education/2486095/A small survey-based study found that dermatology residents from 3 training programs reported limited formal education in topical vehicle formulation science, but showed improved comfort, confidence, and knowledge after a targeted educational intervention.
- ADorable-1 Trial Meets Endpoints for EBGLYSS in Children With Atopic Dermatitishttps://practicaldermatology.com/news/adorable-1-trial-meets-endpoints-for-ebglyss-in-children-with-atopic-dermatitis/2486087/Eli Lilly and Company announced positive topline results from the phase 3 ADorable-1 trial of lebrikizumab-lbkz (Ebglyss) in pediatric patients aged 6 months to 18 years with moderate-to-severe atopic dermatitis (AD), showing the therapy meeting its primary and sec
- FDA Expands Secukinumab to Adolescents With Moderate to Severe HShttps://practicaldermatology.com/news/fda-expands-secukinumab-to-adolescents-with-moderate-to-severe-hs/2486084/The US Food and Drug Administrationv (FDA) has approved secukinumab (Cosentyx, Novartis) for pediatric patients aged 12 years and older with moderate to severe hidradenitis suppurativa (HS), becoming the only IL-17A inhibitor approved for this group, according to a
- Oral Melatonin Shows Benefits for Pruritus, Sleep, and QoL in ADhttps://practicaldermatology.com/news/oral-melatonin-shows-benefits-for-pruritus-sleep-and-qol-in-ad/2485982/Melatonin supplementation significantly improved disease severity and several patient-reported outcomes in adults with mild to moderate atopic de